The bull and bear case for stocks
Anthony Saglimbene, Global Market Strategist – Ameriprise Financial
As of Feb. 16, 2021
- We expect U.S. economic and corporate profit growth to outperform long-term averages this year.
- Boosting vaccination rates is critical to a potential second half surge in business activity.
- More fiscal support is likely on the way with the proposed $1.9 trillion package.
Despite the S&P 500® Index falling in January, major U.S. stock index averages sit at or near all-time highs. As more of the economy recovers from coronavirus impacts, currently elevated stock prices have the opportunity to trace higher yet.
Notably, stock prices often follow economic and profit growth over time. In both areas this year, we expect growth to outperform historical averages. For instance:
- Earnings per share growth for the broader S&P 500 Index turned positive in the fourth quarter of 2020 — the first time since the final quarter of 2019.
- Earnings trends across a broader swath of large U.S. companies accelerated in the fourth quarter and show pandemic effects starting to fade.
As a result, analysts are pushing up profit estimates for this year. Given the material earnings outperformance in the previous quarter, analysts feel more confident about the operating environment and companies’ ability to outperform expectations. Currently, S&P 500 earnings per share is expected to grow roughly +24.0% this year. In our view, such outsized earnings performance, if achieved, would be a strong fundamental driver to help support higher asset prices.
But we believe the distribution of vaccines is the single largest factor likely to drive growth across stocks and the economy this year. The rollout has been slow and uneven across the globe. Investors anticipate more of the U.S. population will receive vaccinations over the coming weeks and months. That is our view as well.
Stock prices have primarily discounted that assumption, increasing the risk for investor disappointment if immunizations remain slow. However, the growing number of vaccines — including prospective vaccines such as Johnson & Johnson's single-shot treatment — could play a vital role in meeting investors' expectations for broader uptake of vaccinations in the second half.
While aggressive new variants of COVID-19 are concerning, health experts believe vaccinations remain the best path of protection. Over time, vaccines may be tweaked to address more virulent strains. Here, investors should focus on overall vaccination rates, which should further help the U.S. economy accelerate this year.
In our view, the U.S. economy could grow by +4.0% in 2021, based on strong fiscal and monetary support as well as broader vaccine availability. However, that growth forecast is subject to potentially higher revisions if the size of the next fiscal stimulus package remains close to $1.9 trillion.
We expect the stimulus package to eventually pass Congress, as both Democrats and Republicans generally agree on more aid for those in need. Yet, both sides are far apart on the size and scale of added relief. In our view, Democrats are likely to use the budget reconciliation process to advance the stimulus package, as they may see their slim majority over the next two years as a small window of opportunity. It's important to remember that markets typically look beyond Washington drama.
Bottom line: There is a tremendous amount of liquidity running through the financial system and supporting asset prices. It appears more could soon be on the way. Regardless of the dollar amount and political efforts toward the next stimulus package, we believe the fiscal side of the equation should remain a tailwind to asset prices.
That said, it is important to highlight both the bull and bear case for stocks. The table below helps balance risks and opportunities in the current environment. In our view, investors are best served if they continue to:
- Employ a modest preference for cyclical value stocks
- Utilize high-quality bonds defensively across a portfolio
- Maintain a well-balanced investment strategy
- Remain constructive on the prospects for the economy and asset prices
|The Bull Case For Stocks||The Bear Case For Stocks|
Data source for indices and sector graphs: Morningstar Direct, as of February 5, 2021.
Past performance is not a guarantee of future results.